Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Antonio Barreiro et al.
Summary: Current COVID-19 vaccines have shown effectiveness in reducing infection rates, severe disease, and mortality. However, due to the continuous evolution of SARS-CoV-2 variants, the development of new accessible vaccines is necessary. This study presents preclinical data on a recombinant protein vaccine, PHH-1V, which was effective in inducing immune responses and preventing mortality in mice infected with SARS-CoV-2 variants.
Article
Health Care Sciences & Services
Julia Corominas et al.
Summary: In the interim results of the Phase IIb HH-2 trial, the SARS-CoV-2 protein-based heterodimer vaccine PHH-1V is shown to have a stronger immunogenicity and higher safety compared to the homologous booster BNT162b2. The PHH-1V booster induces a superior neutralizing antibody response against various SARS-CoV-2 variants and also elicits a strong T-cell response.
LANCET REGIONAL HEALTH-EUROPE
(2023)
Article
Immunology
Alexandra Moros et al.
Summary: The development of a new generation of efficacious vaccines is crucial due to the high global incidence of COVID-19 and low vaccination rates. Researchers have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein fusion of the receptor binding domain (RBD) from the Beta variant of SARS-CoV-2 and the equivalent domain from the Alpha variant. In pig models, PHH-1V has demonstrated excellent safety and has induced a robust immune response to SARS-CoV-2, including neutralising antibodies to multiple variants.
Article
Immunology
David S. Khoury et al.
Summary: Multiple studies have demonstrated a correlation between neutralizing antibody levels and protection from COVID-19, estimating the relationship between the two. However, estimates of the required level of neutralizing antibodies for protection vary across these studies. By normalizing antibody titers, it has been found that there is a consistent relationship between antibody levels and protection from COVID-19. This finding is crucial for future vaccine planning, assessing population immunity, and mitigating the global impact of the COVID-19 pandemic.
EMERGING INFECTIOUS DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Alison Tarke et al.
Summary: T cell responses induced by different vaccine platforms cross-recognize early SARS-CoV-2 variants, while memory B cells and neutralizing antibodies show significant decreases. The majority of memory T cell responses are preserved against variants, with lower recognition of Omicron by memory B cells.
Article
Infectious Diseases
Saranya Sridhar et al.
Summary: This study evaluated the safety and immunogenicity of a SARS-CoV-2 vaccine with different adjuvants and dosing schedules. The results showed that two doses of the vaccine induced robust immune responses in both SARS-CoV-2 naive and non-naive adults, with acceptable safety and reactogenicity. These findings support the progression to phase 3 evaluation of the vaccine.
LANCET INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Zeli Zhang et al.
Summary: Multiple COVID-19 vaccines have successfully protected against symptomatic cases and deaths. Comparisons of T cell, B cell, and antibody responses to different vaccines can provide insights into protective immunity against COVID-19, particularly immune memory. mRNA vaccines and Ad26.COV2.S induced strong T cell responses, while mRNA vaccines showed substantial declines in antibodies.
Article
Medicine, General & Internal
Cristina Menni et al.
Summary: This study investigated the differences in symptom prevalence, risk of hospital admission, and symptom duration between omicron and delta variants of the SARS-CoV-2 virus. The study found that loss of smell was less common in omicron infections, sore throat was more common, and the rate of hospital admission was lower.
Review
Mathematical & Computational Biology
Alison Tarke et al.
Summary: Defining the T cell responses to SARS-CoV-2 and its variants is crucial in understanding adaptive immunity against the infection. Multiple studies have investigated these responses using experimental and bioinformatic approaches. The majority of T cell responses are found to be conserved across all current variants, including Delta and Omicron, suggesting that T cells can still provide antiviral immunity even with reduced antibody and B cell responses.
FRONTIERS IN BIOINFORMATICS
(2022)
Article
Cell Biology
Edwards Pradenas et al.
Summary: This study follows a cohort of 332 COVID-19 patients for over a year to understand the long-term immune responses to SARS-CoV-2. The study finds that long-term neutralizing activity remains stable beyond one year after infection in mild/asymptomatic and hospitalized participants. It also shows that hospitalized individuals generate both short-term and long-term memory B cells, while non-hospitalized individuals have dominant long-term B cells. Vaccination boosts responses to natural infection, but unvaccinated participants show reduced efficacy against the beta variant.
CELL REPORTS MEDICINE
(2022)
News Item
Multidisciplinary Sciences
Elie Dolgin
Article
Medicine, General & Internal
Peter Richmond et al.
Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.
News Item
Medicine, General & Internal
Mun-Keat Looi
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Immunology
Harry Kleanthous et al.
Summary: Global vaccination against COVID-19 poses significant challenges in science, logistics, and ethics, with a need for safe, effective, high-volume, affordable vaccines; RBD-based vaccines may be a solution for filling the gap in global demand, offering high production potential and cost-effectiveness as a sole vaccine immunogen.
Article
Infectious Diseases
Shilong Yang et al.
Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.
LANCET INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Review
Immunology
Qian He et al.
Summary: The world is facing the second wave of the COVID-19 pandemic, with a higher intensity than the first wave of early 2020. Multiple COVID-19 vaccine candidates have been developed and are undergoing clinical testing to rapidly respond to the global pandemic. Evaluating and defining effective vaccine candidates is crucial for prioritizing vaccination programs against COVID-19.
FRONTIERS IN IMMUNOLOGY
(2021)
Editorial Material
Biochemistry & Molecular Biology
Florian Krammer
Article
Cell Biology
Allison J. Greaney et al.
Summary: Vaccine-elicited antibodies have more focused neutralizing activity on the RBD of the SARS-CoV-2 spike protein, while infection-elicited antibodies have broader binding across epitopes; hence, single RBD mutations have less impact on neutralization by vaccine sera.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Allison J. Greaney et al.
Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Alison Tarke et al.
Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.
CELL REPORTS MEDICINE
(2021)
Article
Medicine, Research & Experimental
Edwards Pradenas et al.
Summary: The study found that individuals with mild or asymptomatic infections experienced an insignificant decrease in neutralizing activity, which persisted for 6 months after symptom onset or diagnosis. Hospitalized individuals exhibited higher neutralizing titers, which decreased rapidly at first but significantly slowed down after day 80, remaining higher than those with mild symptoms at 6 months. This slow decline in neutralizing activity contrasted with the constant decrease in anti-RBD, S2, or NP antibody titers over the follow-up period.
Review
Immunology
Lianpan Dai et al.
Summary: The urgent need for vaccines to control the COVID-19 pandemic has led to the rapid development of multiple vaccine candidates, with some showing positive results in late-stage clinical trials. This article discusses the viral elements used in these candidates, the reasons why they are good targets for the immune system, and their implications for protective immunity. Dai and Gao highlight the importance of selecting the right viral targets in vaccine development to ensure an effective immune response and the overall safety and efficacy of the vaccine.
NATURE REVIEWS IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Jun Lan et al.
Article
Biochemistry & Molecular Biology
Lianpan Dai et al.
Article
Medicine, General & Internal
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
